DexCom vs Senseonics Which Is Superior?

DexCom and Senseonics are two companies competing in the growing market of continuous glucose monitoring technology. DexCom, a well-established player in the industry, offers a range of innovative devices that provide accurate and real-time glucose monitoring for patients with diabetes. Senseonics, on the other hand, is a smaller but rapidly growing company that has developed a unique implantable sensor system for continuous glucose monitoring. Both companies have seen fluctuations in their stock prices as they seek to capture market share and innovate in the fast-evolving medical technology landscape.

DexCom or Senseonics?

When comparing DexCom and Senseonics, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between DexCom and Senseonics.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. DexCom has a dividend yield of -%, while Senseonics has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. DexCom reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Senseonics reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with DexCom P/E ratio at 43.24 and Senseonics's P/E ratio at -2.19. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. DexCom P/B ratio is 14.88 while Senseonics's P/B ratio is 4.68.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, DexCom has seen a 5-year revenue growth of 2.21%, while Senseonics's is -0.67%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with DexCom's ROE at 31.20% and Senseonics's ROE at -156.01%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $71.75 for DexCom and $0.28 for Senseonics. Over the past year, DexCom's prices ranged from $62.34 to $142.00, with a yearly change of 127.78%. Senseonics's prices fluctuated between $0.28 and $0.75, with a yearly change of 172.73%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.